Drugs / COMVIGEN
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05930730 | Oct 2023 → Feb 2024 | — | Chulalongkorn University | Unknown | No outcome recorded |
| Phase 2 | NCT05605470 | Jan 2023 → Jul 2024 | COVID-19 | Technovalia, Pty Ltd | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COMVIGEN | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05605470 ↗ |
| Known as | ChulaCov19 BNA159.2 | “Comvigen (Bivalent, ChulaCov19 BNA159.2)” NCT05930730 ↗ |
| Modality | Vaccine | “COMVIGEN (ChulaCov19 BNA159.2) vaccine (50 mcg)” NCT05605470 ↗ |
| Route | Intramuscular | “Single dose of COMVIGEN vaccine 0.5 ml will be given by IM at Day 1” NCT05605470 ↗ |